QURE Dec 2023 12.500 put

OPR - OPR Delayed price. Currency in USD
2.2500
0.0000 (0.00%)
As of 04:27PM EDT. Market open.
Stock chart is not supported by your current browser
Previous close2.2500
Open2.2500
Bid0.1000
Ask3.4000
Strike12.50
Expiry date2023-12-15
Day's range2.2500 - 2.2500
Contract rangeN/A
Volume1
Open interestN/A
  • GlobeNewswire

    uniQure Announces Sale of Royalty Interest in HEMGENIX® for Up To $400 Million

    ~ uniQure to receive $375 million upfront cash payment ~ ~ Under the existing agreement with CSL Behring, uniQure retains the rights to future milestones totaling up to $1.5 billion and maintains an interest in HEMGENIX® royalties ~ ~ Capped royalty financing provides uniQure non-equity-dilutive capital to advance its broad gene therapy pipeline, including AMT-130 for Huntington’s disease ~ LEXINGTON, Mass. and AMSTERDAM, The Netherlands, May 15, 2023 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QU

  • Simply Wall St.

    The Consensus EPS Estimates For uniQure N.V. (NASDAQ:QURE) Just Fell Dramatically

    The latest analyst coverage could presage a bad day for uniQure N.V. ( NASDAQ:QURE ), with the analysts making...

  • Zacks

    UniQure (QURE) Reports Q1 Loss, Lags Revenue Estimates

    uniQure (QURE) delivered earnings and revenue surprises of -59.80% and 79.68%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

  • GlobeNewswire

    uniQure Announces First Quarter 2023 Financial Results and Highlights Recent Company Progress

    ~ Clinical update from U.S. Phase I/II trial in Huntington’s disease expected in second quarter 2023 ~ ~ Continued progress towards initiating two new Phase I/II clinical studies for AMT-260 in refractory temporal lobe epilepsy and AMT-162 in SOD1-ALS ~ LEXINGTON, Mass and AMSTERDAM, the Netherlands, May 09, 2023 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today reported its financial r

  • GlobeNewswire

    uniQure Announces Major Presence at Upcoming American Society of Gene and Cell Therapy (ASGCT) Annual Meeting

    LEXINGTON, Mass. and AMSTERDAM, May 02, 2023 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced that 12 data presentations, including two oral presentations, will be delivered at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting being held May 16-20 in Los Angeles, California. “Our presentations at ASGCT highlight the innovative work of our uniQure research s

  • GlobeNewswire

    uniQure Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    LEXINGTON, Mass. and AMSTERDAM, May 02, 2023 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced that the Company granted equity awards to 38 employees as a material inducement to commencing their employment. The equity awards were approved by the Company’s board of directors on April 24, 2023 (the “Grant Date”) in accordance with Nasdaq Listing Rule 5635(c)(4). In the aggregate

  • Simply Wall St.

    uniQure N.V.'s (NASDAQ:QURE) Price Is Right But Growth Is Lacking

    uniQure N.V.'s ( NASDAQ:QURE ) price-to-sales (or "P/S") ratio of 8.6x might make it look like a buy right now compared...

  • Zacks

    Are Options Traders Betting on a Big Move in UniQure (QURE) Stock?

    Investors need to pay close attention to UniQure (QURE) stock based on the movements in the options market lately.

  • GlobeNewswire

    uniQure to Participate in Multiple Upcoming Industry Conferences in March

    LEXINGTON, Mass. and AMSTERDAM, the Netherlands, March 02, 2023 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced its participation in the following upcoming investor and scientific conferences: Cowen Annual Healthcare Conference, March 6 – 8, 2023 Boston, MA Members of uniQure’s management team, including Matt Kapusta, chief executive officer, will participate in one-on-one i

  • Zacks

    UniQure (QURE) Tops Q4 Earnings and Revenue Estimates

    uniQure (QURE) delivered earnings and revenue surprises of 128.85% and 85.55%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

  • GlobeNewswire

    uniQure Announces 2022 Financial Results and Highlights Recent Company Progress

    ~ Achieved U.S. and European Commission marketing approvals of first and only gene therapyfor adults with hemophilia B ~ ~ Advancing development of AMT-130 for patients with Huntington’s disease – clinical update from U.S. Phase I/II trial expected in second quarter 2023 ~ ~Hosted virtual investor event featuring AMT-260 in refractory temporal lobe epilepsy - expected to enter clinical development in second half of 2023 ~ ~Expanded pipeline with in-licensing of AMT-162 for SOD1 ALS - plans to in

  • GlobeNewswire

    uniQure Announces HOPE-B Clinical Trial Data Published in the New England Journal of Medicine, Demonstrating Durability and Other Benefits of HEMGENIX® (etranacogene dezaparvovec-drlb)

    ~ Data follow the historic approval of the first gene therapy for hemophilia B, which has been shown in clinical trials to reduce the rate of annual bleeds, reduce or eliminate the need for prophylactic therapy and generate elevated and sustained factor IX levels for years after a one-time infusion ~ ~ 18-month data support the ongoing benefit of HEMGENIX® ~ ~ HEMGENIX® is approved for adults with hemophilia B in the United States, European Union and European Economic Area ~ LEXINGTON, Mass. and

  • PR Newswire

    CSL's HOPE-B Data Published in the New England Journal of Medicine, Demonstrating Efficacy and Durability of HEMGENIX® (etranacogene dezaparvovec-drlb)

    Global biotechnology leader CSL (ASX: CSL) today announced the publication in the New England Journal of Medicine (NEJM) (Vol. 388 No. 8) results from the pivotal HOPE-B clinical study evaluating the efficacy, durability and safety of HEMGENIX® (etranacogene dezaparvovec-drlb). HEMGENIX® is the first and only gene therapy approved for the treatment of adults with hemophilia B who currently use factor IX prophylaxis therapy, or have current or historical life-threatening bleeding, or have repeate

  • GlobeNewswire

    uniQure announces the European Commission approval of the first gene therapy for adults with hemophilia B

    ~ Historic approval represents the first gene therapy in Europe to treat hemophilia B and provides a new treatment option for patients that reduces the rate of annual bleeds, reduces or eliminates the need for prophylactic therapy, and generates elevated and sustained factor IX levels ~ ~ Approval marks uniQure’s second internally-developed and manufactured gene therapy to achieve licensure in the European Union ~ LEXINGTON, Mass. and AMSTERDAM, Feb. 21, 2023 (GLOBE NEWSWIRE) -- uniQure N.V. (NA

  • GlobeNewswire

    uniQure and Apic Bio enter into global licensing agreement for APB-102, a clinical stage gene therapy for patients with ALS caused by mutations in SOD1

    ~ License of APB-102 further strengthens uniQure’s pipeline of innovative gene therapies to treat neurological disorders and miRNA-based gene silencing programs ~ ~ APB-102 and uniQure’s c9orf72-ALS program have the potential to address most inherited forms of ALS ~~ uniQure plans to initiate a Phase I/II trial of APB-102 in the second half of 2023 ~ LEXINGTON, Mass. and AMSTERDAM and CAMBRIDGE, Mass., Jan. 31, 2023 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company

  • Motley Fool

    3 Growth Stocks That Could Rocket Higher in 2023

    If you're looking for stocks that can make dramatic gains quickly, it's hard to do any better than the biotechnology industry. Hardly a week goes by without at least one biotech stock shooting higher or tumbling lower in response to exciting news about experimental treatments. In 2023, all three of these drugmakers will report study results that are awfully important to their futures.

  • GlobeNewswire

    uniQure announces positive CHMP opinion for etranacogene dezaparvovec – gene therapy for adults with hemophilia B

    If approved, etranacogene dezaparvovec would be the first licensed gene therapy in Europe for people living with hemophilia BLEXINGTON, Mass. and AMSTERDAM, Dec. 16, 2022 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, announced that its partner, global biotechnology leader CSL (ASX: CSL), has received a positive opinion recommending conditional marketing authorization (CMA) for etranacogen

  • PR Newswire

    CSL's Novel Gene Therapy HEMGENIX® (etranacogene dezaparvovec-drlb) Demonstrates Durable Protection and Sustained Factor IX Activity Levels for People Living with Hemophilia B at 24-Months Post-Treatment

    Global biotechnology leader CSL (ASX: CSL) today announced the presentation of data affirming the long-term durability and safety of single-infusion HEMGENIX® (etranacogene dezaparvovec-drlb) in the treatment of certain adults living with hemophilia B at the 64th American Society of Hematology (ASH) Annual Meeting. Results from the pivotal HOPE-B study, the largest gene therapy study in hemophilia B to date, demonstrated that after two years of follow-up, adults with severe or moderately severe

  • GlobeNewswire

    uniQure Highlights Therapeutic Potential of AMT-260 in Refractory Temporal Lobe Epilepsy (rTLE) at Virtual Research & Development Event

    ~ IND Submission and Clinical Development Expected to Begin in 2023 ~ ~ Advancements in Manufacturing and Technology Platform Also Highlighted ~ LEXINGTON, Mass. and AMSTERDAM, the Netherlands, Nov. 29, 2022 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, hosted a virtual investor event focused on AMT-260, an AAV gene therapy for refractory temporal lobe epilepsy (rTLE) and other focal epil

  • Motley Fool

    Why Shares of uniQure Rose 14.61% on Wednesday

    Shares of uniQure (NASDAQ: QURE) climbed 14.61% on Wednesday. The stock jumped after the Food and Drug Administration (FDA), on Tuesday, approved Hemgenix (etranacogene dezaparvovec-drlb), a one-time gene therapy for hemophilia B. It was developed by uniQure, but CSL will commercialize the therapy. Hemophilia B, also known as Christmas disease, is rare.

  • Zacks

    uniQure (QURE) Partner Gets FDA Nod for Hemophilia B Gene Therapy

    uniQure (QURE) shares rise after its partner CSL Limited received FDA nod for one-time gene therapy, Hemgenix, for treating adults with Hemophilia B.

  • GlobeNewswire

    uniQure announces FDA approval of first gene therapy for adults with hemophilia B

    Lexington Facility uniQure's commercial manufacturing facility in Lexington, MA Manufacturing State-of-the-art global commercial manufacturing at uniQure ~ Historic approval provides a new treatment option that reduces the rate of annual bleeds, reduces or eliminates the need for prophylactic therapy, and generates elevated and sustained factor IX levels ~ ~ uniQure conducted the multi-year clinical development program and will now leverage its leading gene therapy manufacturing capabilities to

  • PR Newswire

    U.S. Food and Drug Administration approves CSL's HEMGENIX® (etranacogene dezaparvovec-drlb), the first gene therapy for hemophilia B

    Global biotechnology leader CSL (ASX: CSL) today announced that the U.S. Food and Drug Administration (FDA) approved HEMGENIX® (etranacogene dezaparvovec-drlb), the first and only one-time gene therapy for appropriate adults with hemophilia B. HEMGENIX is approved for the treatment of adults with hemophilia B who currently use factor IX prophylaxis therapy, or have current or historical life-threatening hemorrhage or have repeated, serious spontaneous bleeding episodes. In the ongoing clinical t

  • GlobeNewswire

    uniQure to Host Virtual Research & Development Event on Tuesday, November 29, 2022

    ~ Event to be Webcast Live on uniQure’s Corporate Website at 8:30 a.m. EST ~ LEXINGTON, Ma. and AMSTERDAM, Nov. 17, 2022 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced that it will host a Virtual Research & Development Event on Tuesday, November 29, 2022 from 8:30 a.m. to 10:30 a.m. EST. The event will focus on the unmet medical need of patients with refractory temporal lob

  • Simply Wall St.

    uniQure (NASDAQ:QURE shareholders incur further losses as stock declines 8.3% this week, taking three-year losses to 66%

    Investing in stocks inevitably means buying into some companies that perform poorly. But long term uniQure N.V...